In vitro activity of Cefiderocol against Gram-negative pathogens isolated from people with cystic fibrosis and bronchiectasis.

CS McLaughlin,JS Elborn,CM Longshaw,Tunney MM

DOI: https://doi.org/10.1016/j.jgar.2024.01.023

IF: 4.349

2024-02-10

Journal of Global Antimicrobial Resistance

Abstract:Objectives Gram-negative pathogens causing respiratory infection in people with cystic fibrosis and bronchiectasis are becoming progressively more resistant to conventional antibiotics. Although cefiderocol is licensed for the treatment of infections due to Gram-negative organisms, there is limited data on the activity of cefiderocol against pathogens associated with chronic respiratory diseases. The aim of this study was to determine the susceptibility of Gram-negative pathogens from cystic fibrosis and bronchiectasis to cefiderocol and comparator antibiotics. Methods Minimal inhibitory concentrations (MICs) of cefiderocol and 15 comparator antibiotics were determined by broth microdilution against 300 respiratory isolates: Burkholderia spp., Stenotrophomonas spp., Achromobacter spp., Ralstonia spp. and Pandoraea spp. and used to calculate the MIC of each antibiotic required to inhibit 50% (MIC 50 ) and 90% (MIC 90 ) of isolates. Results The MIC 50 and MIC 90 of cefiderocol for all 300 isolates tested was 0.25 and 32 mg/L with 232 (77.3%) isolates having an MIC value ≤2 mg/L. In addition, cefiderocol demonstrated excellent activity against Stenotrophomonas spp. and Achromobacter spp. isolates with 86.7% and 87.2%, respectively, exhibiting an MIC of 2 mg/L. Tigecycline also demonstrated good activity against all isolates with an MIC 50 of <0.5 mg/L. Conclusions These in vitro data demonstrated that cefiderocol had greater activity than most comparator antibiotics and could be an alternative treatment option for respiratory infection caused by these pathogens that has not responded to first line therapy.

pharmacology & pharmacy,infectious diseases